Revenue increased 4.1% YoY to 78,896.0 million yen; operating income decreased 19.6% YoY to 5,596.0 million yen; ordinary income decreased 20.5% YoY to 6,088.0 million yen; net income attributable to owners of the parent decreased 50.5% YoY to 2,476.0 million yen. Full-year guidance unchanged, dividend forecast unchanged. Segment-wise, Medical Pharmaceuticals Wholesale: revenue 70,900.0 million yen, operating income 6,600.0 million yen; Self-Medication Wholesale: revenue 66,100.0 million yen, operating income 500.0 million yen; Manufacturing: revenue 11,900.0 million yen, operating loss 600.0 million yen; Dispensing Pharmacies: revenue 9,400.0 million yen, operating loss 400.0 million yen. New consolidation of ArkMS and investment in regenerative medicine continue. Share buyback is ongoing.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2784","jir_company_name":"Alfresa Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2784-20260805-01.pdf","jir_short_summary":"Revenue increased 4.1% YoY to 78,896.0 million yen; operating income decreased 19.6% YoY to 5,596.0 million yen; ordinary income decreased 20.5% YoY to 6,088.0 million yen; net income attributable to owners of the parent decreased 50.5% YoY to 2,476.0 million yen. Full-year guidance unchanged, dividend forecast unchanged. Segment-wise, Medical Pharmaceuticals Wholesale: revenue 70,900.0 million yen, operating income 6,600.0 million yen; Self-Medication Wholesale: revenue 66,100.0 million yen, operating income 500.0 million yen; Manufacturing: revenue 11,900.0 million yen, operating loss 600.0 million yen; Dispensing Pharmacies: revenue 9,400.0 million yen, operating loss 400.0 million yen. New consolidation of ArkMS and investment in regenerative medicine continue. Share buyback is ongoing.","jir_summary":"### Performance Overview\nAlfresa Holdings recorded steady revenue in the first quarter of fiscal 2027, but operating income, ordinary income, and net income attributable to owners of the parent declined versus the same period a year earlier. Segment-wise, revenue remained solid in Medical Pharmaceuticals Wholesale and Self-M Medications Wholesale, though price revisions and rising logistics costs pressured profits. The company continued to add new consolidated subsidiary ArkMS and invest in regenerative medicine-related businesses to strengthen growth areas. Share buybacks are continuing as part of its capital policy.\n\n### Outlook and Investor Impact\nNo change to full-year guidance. Expectations show continued impact from drug price revisions and logistics costs; improving profitability will require ongoing cost management and contributions from new businesses. Strategic investments in medical devices and regenerative medicine will continue, with efforts to advance a highly efficient supply chain centered on TSCS. Expanding treasury stock holdings aims to enhance shareholder returns.","jir_financial_highlights":"Revenue: 78,896\u767e\u4e07\u5186 (YoY +4.1%)\nOperating Income: 5,596\u767e\u4e07\u5186 (YoY \u25b319.6%)\nOrdinary Income: 6,088\u767e\u4e07\u5186 (YoY \u25b320.5%)\nNet Income Attributable to Owners of the Parent: 2,476\u767e\u4e07\u5186 (YoY \u25b350.5%)\nTreasury stock: 36,543\u767e\u4e07\u5186\uff08\u671f\u672b\uff09 (Increase vs prior period)","jir_category":"","jir_hashtags":"#AlfresaHoldings, #financial_summary, #JapanStocks","jir_key_figures":"Revenue: 78,896\u767e\u4e07\u5186\uff08YoY +4.1\uff05\uff09\nOperating Income: 5,596\u767e\u4e07\u5186\uff08YoY \u25b319.6\uff05\uff09\nNet Income Attributable to Owners of the Parent: 2,476\u767e\u4e07\u5186\uff08YoY \u25b350.5\uff05\uff09","jir_meta_title":"Alfresa Holdings: Q1 FY2027 Financial Results\uff5cRevenue over 37.70 billion yen \/ Operating income declines","jir_meta_description":"Key points from Alfresa Holdings' Q1 FY2027 financial results. Summary of revenue, operating income, ordinary income, and net income, segment-by-segment status, outlook for the current period, and share buyback activity.","jir_og_title":"Alfresa Holdings Q1 Financial Results Summary","jir_og_description":"Alfresa Holdings Q1 results. Revenue rose while profits declined, with segment trends and investment strategy, plus share buyback status explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026Q1\\\",\\\"2026Q2\\\",\\\"2026Q3\\\",\\\"2026Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (million yen)\\\",\\\"data\\\":[788960,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026Q1\\\",\\\"2026Q2\\\",\\\"2026Q3\\\",\\\"2026Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (million yen)\\\",\\\"data\\\":[5596,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Medical Pharmaceuticals Wholesale\\\",\\\"Self-Medication Wholesale\\\",\\\"Manufacturing\\\",\\\"Dispensing Pharmacies\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (million yen)\\\",\\\"data\\\":[709? ,661? ,119? ,94? ,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profitability\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Medical Pharmaceuticals Wholesale\\\",\\\"Self-Medication Wholesale\\\",\\\"Manufacturing\\\",\\\"Dispensing Pharmacies\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Segment Profit (million yen)\\\",\\\"data\\\":[6637,537,-618,-498]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Full-Year Guidance vs Actual\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Quarter-to-date\\\",\\\"Full Year\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue Guidance\\\",\\\"data\\\":[0,0]},{\\\"label\\\":\\\"Revenue Actual\\\",\\\"data\\\":[788960,788960]}]},\\\"options\\\":{}}\"}]","ir_related_company":7908,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-94805","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n